Johnson & Johnson vs. Pfizer Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 8 of 11 compared factors.
Size & Scale
| JNJ | PFE | |
|---|---|---|
| Market Cap | $644.33 billion | $160.96 billion |
| Revenue (TTM) | $97.93 billion | $63.70 billion |
| Net Income (TTM) | $21.04 billion | $4.37 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 31.35 | 36.76 |
| Price / Book | 7.58 | 1.88 |
| Price / Sales | 6.58 | 2.53 |
PFE leads on 2 of 3 valuation factors.
Profitability
| JNJ | PFE | |
|---|---|---|
| Net Margin | 21.48% | 6.86% |
| Return on Equity | 24.76% | 5.11% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | PFE | |
|---|---|---|
| Dividend Yield | 1.98% | 6.16% |
| Payout Ratio | 62.18 | 226.32 |
JNJ and PFE split the dividend factors evenly.
Risk & Sentiment
| JNJ | PFE | |
|---|---|---|
| Short Interest | 0.67% | 0.88% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, PFE overview, PFE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.